Detailed Information on Publication Record
2020
Diagnostic relevance of 18F-FDG PET/CT in newly diagnosed patients with monoclonal gammopathy of undetermined significance (MGUS): Single-center experience
SANDECKÁ, Viera, Zdeněk ADAM, Marta KREJČÍ, Martin ŠTORK, Zdeněk ŘEHÁK et. al.Basic information
Original name
Diagnostic relevance of 18F-FDG PET/CT in newly diagnosed patients with monoclonal gammopathy of undetermined significance (MGUS): Single-center experience
Authors
SANDECKÁ, Viera (703 Slovakia), Zdeněk ADAM (203 Czech Republic), Marta KREJČÍ (203 Czech Republic), Martin ŠTORK (203 Czech Republic, guarantor), Zdeněk ŘEHÁK (203 Czech Republic), Renata KOUKALOVÁ (203 Czech Republic), Sabina ŠEVČÍKOVÁ (203 Czech Republic, belonging to the institution), Lucie BROŽOVÁ (203 Czech Republic, belonging to the institution), Zdeněk KRÁL (203 Czech Republic), Jiří MAYER (203 Czech Republic) and Luděk POUR (203 Czech Republic)
Edition
Neoplasma, Bratislava, Slovenská akademie vied, 2020, 0028-2685
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30204 Oncology
Country of publisher
Slovakia
Confidentiality degree
není předmětem státního či obchodního tajemství
References:
Impact factor
Impact factor: 2.575
RIV identification code
RIV/00216224:14110/20:00116304
Organization unit
Faculty of Medicine
UT WoS
000557901000025
Keywords in English
monoclonal gammopathy; cancer; multiple myeloma; PET/CT
Tags
International impact, Reviewed
Změněno: 1/9/2020 09:08, Mgr. Tereza Miškechová
Abstract
V originále
Monoclonal gammopathy of undetermined significance (MGUS) is a known precursor of more serious cancers, such as multiple myeloma (MM), Waldenstrom macroglobulinemia (MW) and other lymphoproliferative disorders. Using 18F-FDG PET/CT, we aimed to evaluate its benefit in early detection of various accompanying disorders and illnesses in MGUS patients. We prospectively analyzed the diagnostic relevance of 18F-FDG PET/CT in 390 newly diagnosed MGUS patients. On 18F-FDG PET/CT scans, the presence of focal or diffuse areas of detectable increased tracer uptake was recorded in 37 (9.5%) MGUS patients. The most frequent pathology was lymphadenopathy (3.8%), followed by thyroid diseases (2.1%), rheumatic diseases (1.8%), and other solid malignancies (1.5%). These results have major implications for confirmed associations of MGUS with numerous malignant and non-malignant disorders. We believe that 18F-FDG PET/CT imaging in newly diagnosed MGUS patients may be useful in early detection of other serious pathologies, not only in predicting progression of MGUS to active MM, and should be strongly recommended if available.